Compare RCI & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCI | INCY |
|---|---|---|
| Founded | 1960 | 1991 |
| Country | Canada | United States |
| Employees | 24000 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 17.0B |
| IPO Year | N/A | 1994 |
| Metric | RCI | INCY |
|---|---|---|
| Price | $36.51 | $100.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 21 |
| Target Price | $44.00 | ★ $103.52 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $6.78 | $10.44 |
| Revenue Next Year | $1.45 | $10.99 |
| P/E Ratio | ★ $4.12 | $67.09 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $24.80 | $62.84 |
| 52 Week High | $41.14 | $112.29 |
| Indicator | RCI | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 59.56 |
| Support Level | $35.74 | $99.10 |
| Resistance Level | $38.86 | $102.07 |
| Average True Range (ATR) | 0.96 | 3.17 |
| MACD | 0.22 | 0.32 |
| Stochastic Oscillator | 54.35 | 74.84 |
Rogers Communications is the largest wireless service provider in Canada with more than 11 million subscribers, equating to one-third of the total Canadian market. Rogers' wireless business accounts for more than half of total revenue and has been growing at a higher rate than other segments. The cable segment, which provides about 38% of total revenue after acquiring Shaw, offers home internet, television, and landline phone service to consumers and businesses. Remaining sales come from Rogers' media unit, which owns and operates various television and radio stations and major Toronto sports franchises, including the Blue Jays, Maple Leafs, Raptors, Toronto FC, and Argonauts.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.